Rett-T
Phase 2Small molecule
Rett-T is one of 26 small molecule programs targeting Rett syndrome. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
30 competitors in Rett Syndrome
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Norpramin
VValidus Pharmaceuticals
Approved
Risperdal
WWim Janssens
Approved
GWP42003-P
Jazz PharmaceuticalsPhase 3
Donepezil Hydrochloride
EisaiPhase 3
Robitussin
PfizerPhase 2
Copaxone
TevaPhase 2
Dojolvi
UltragenyxPhase 2
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Ketalar
AAultman Health Foundation
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rett-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details